

Rathbone Strategic Growth Portfolio

Quarterly investment update, July to end September 2021



Rathbones
Look forward

Hot topics – ‘Top-down’ (market and macroeconomic)

Gaslighting. The price of natural gas has risen rapidly this year all over Europe, driven by a cooler summer ratchetting up demand alongside the reopening of many nations after lockdowns. The European carbon credit price (the cost of emitting a tonne of carbon dioxide) has soared more than 80% since the beginning of the year, a sign of much-increased demand from industry and/or increased power generation by carbon-heavy producers, like coal plants. The energy crunch is most acute here in the UK, however, where the gas price is four times what it was at the beginning of the year. At one point in September it was 85% higher than the last record high posted in 2008. We think this is a bit of a reality check on our progress towards cleaner energy. Everyone agrees with the need to change – and quickly – but perhaps more



thought needs to go into ensuring our network is set up for the new world. Because if the strategy isn't right it risks times like we're experiencing, where prices balloon, hitting people in the pocket and potentially turning them off green energy altogether. About half of the UK's electricity is generated with gas, and that only accounts for 30% of the gas we use. Fully 40% is used to heat homes and fire gas cookers, with the rest going to industry. Along with petrol, the single most crucial element of UK energy is natural gas. Yet the UK has one of the lowest gas storage capacities in Europe, with enough to cover just four to five winter days of demand. In 2017, a 30-year-old Centrica-run storage facility boasting 70% of the nation's tanks was shuttered because the company and the government didn't see the benefit in paying for the costly upkeep and essential upgrades of the site. Meanwhile, the best days are behind the North Sea gas fields, making the UK more reliant on imported gas. We have done extremely well to boost our renewable generation and dramatically reduce our carbon emissions. But there's still a long way to go. As maligned as oil and gas are, virtually everything in our society relies on them. Whether for comfort, production, packaging, transportation, or all four. This needs to change if we are to avoid dramatically altering our planet. Yet today, despite all our efforts to change, if oil and gas disappear, you're going to know about it.

Inflated importance. As economies try to get back into their rhythm, dogged by interminable waves of COVID-19, markets for everything from labour and energy to bread and computer chips have been upended. This has sent inflation bouncing higher in most of the world as businesses struggle to attract staff and buy the essentials. Currently inflation is higher in the US, at a 13-year record of 5.4%, yet it's the UK that concerns us more. The headline rate was 3.2% in August, but September and October have been chock-full of shortages: fuel, gas, staff, groceries and other imported goods. These are global issues, but they have hit the UK harder because of poor energy storage and bad labour market policies. All this puts the Bank of England (BoE) in a difficult position: its policymakers have about as much idea of the path of inflation over the coming year or two as any of us in these strange times. It's tough to tell. British inflation is almost definitely going higher in coming months. But this sort of inflation – ‘cost-push’, driven by higher supply costs – isn't the sort that can be solved by higher interest rates. Raising rates can only reduce households'



and businesses' demand for goods and services by increasing the cost of borrowing and boosting the incentive to save rather than spend. Raising rates can't get the fuel to the pumps quicker, make it rain for the soybean crops in Brazil, grease the export of raw materials from COVID-cagey Australia or open ports in China. If the BoE acts too quickly, it could simply make things worse. It may even spark stagflation – putting the economy into reverse while persistent inflation eats away at people's spending power.

(N)Evergrande. China has battled a dangerously inflated property boom for many years now. Developers borrowed heavily from investors all around the world, using the cheap debt to finance countless apartment blocks and houses thrown up all over China. Demand for these homes, both as abodes and investments, was huge. However, many companies overstretched themselves, repaying maturing debt with ever more debt as they chased sales growth. This has finally come to a head with Evergrande, China's largest real estate developer defaulting on debt and



essentially becoming the world's largest zombie company after China tightened up leverage rules. The government is trying to stop runaway price inflation in homes and encourage developers to become more financially responsible. It seems to have had the desired effect on property prices, but it may also destroy developers rather than bring them to heel. Concerns about Evergrande and its aftermath have hit the Hong Kong stock market the hardest. The satellite market – which used to be the largest in China and is typically used by overseas investors – came off worse following the government's recent crackdowns on technology and education businesses as well. Investors are worried that China may allow Evergrande to fail in the messiest possible fashion as a warning to the others. If so, this could set off a wildfire of fear, fire sales and plummeting prosperity that would dramatically slow Chinese GDP growth. That would have a knock-on effect for the whole world. We think China is unlikely to allow this own goal to happen. We expect the government to wind down Evergrande over the coming years, parcelling parts off to state-owned banks, perhaps creating a bad bank for the most toxic assets and letting bondholders take a bath.

Portfolio activity

| Key purchases/additions | Key sales/trims |
|--|---|
| Societe Generale US rates volatility note (new purchase) | iShares MSCI Far East Ex-Japan ETF (sale) |
| Canada Government 0.5% 2030 (addition) | Dexcom (trim) |
| iShares China CNY Bond ETF (addition) | Eurofins Scientific (trim) |
| JP Morgan Emerging Markets FX Momentum Structured Product (addition) | Adobe (trim) |
| US Treasury Inflation-Protected Securities 0.25% 2025 (addition) | ASML (trim) |

Source: Rathbones

Because bond yields are so low, it makes stocks, bonds and property all expensive. This means it's harder to reduce the correlation of portfolio returns – to ensure that everything we hold isn't going up or down together – which is a key measure of our risk. To boost our diversification over the past year or so, we have bought several different structured products, which are contract-based investments with banks. That means that if certain events happen or market measures hit certain targets, we are paid a certain return, while if the opposite happens, we lose the return and sometimes some of our capital. It depends on the product. The most recent is the **Societe Generale US rates volatility note**, which makes money if the volatility of US Treasury yields increases. So, if yields rise rapidly because of an inflation scare or if they slump because of GDP growth concerns we make a return. Any increase in the size or frequency of moves in US treasury yields is good for this investment. However, if yields just amble along with little movement, we will lose money. And we would actually prefer the latter: if yields shoot up or down stocks are likely to be falling because of the fears driving the move. Whereas benign yields should be great for our stocks. Long story short, we view this product as an insurance policy for wobbly markets.

As a defence against a sustained uptick in inflation, we added a lot of **US Treasury Inflation-Protected Securities 0.25% 2025 bonds (TIPS)**, whose coupons and principal are linked to US CPI. The average rate of inflation required over the life of the bonds to make these bonds more profitable than conventional US Treasuries – which is known as the “breakeven rate” – has fallen back slightly in recent months.

We added to the **iShares China CNY Bond ETF**, which invests in investment-grade bonds issued by the Chinese government and state-run development banks to further diversify our currency exposure. These bonds should also hedge us against a global economic slowdown as that would send their yields lower, while giving us better interest rates than we could get in the West. We also added to the **JP Morgan Emerging Markets FX Momentum Structured Product**. This contract gives us exposure to a ‘momentum’ index of emerging market currencies. It uses price trend data to try to anticipate whether the basket of currencies will rise or fall against the dollar. This should enable us to generate positive returns in benign markets, and historically it has provided some protection in times of crisis as emerging market currencies typically sell off against the dollar, and the index model has picked up on this trend and moved to a long dollar position.

While we expect the pandemic-driven supply-demand imbalances will be sorted out by the market in good time, there is definitely the risk of commodity prices continuing to rise and staying high for some time. To protect ourselves against this, we added to our holdings of **Canada Government 0.5% 2030** bonds (Canada receives a lot of cash from royalties on oil extraction). We should also benefit from currency appreciation if higher commodity prices heighten UK inflation and send the pound lower.

Meanwhile, we sold the **iShares MSCI Far East Ex-Japan ETF** to reduce our Asian exposure. And we took profits from some of our more high-flying stocks, including laboratory network **Eurofins Scientific**, diabetes monitoring business **Dexcom** and creative software developer **Adobe**.

Spotlight

In this quarter, the spotlight is on our holdings **Adobe** and **Christian Hansen**.



Adobe

- A US software company that creates digital media, design and publication tools for professionals and hobbyists alike
- Outside of the pros most will know Adobe for the PDF which has become a mainstay of the digital document world
- Adobe's expansion into areas like digital marketing software, cloud collaboration and document digitisation provide further drivers of growth in the future
- Like many software companies, Adobe moved from licensing to subscriptions, which has provided attractive levels of cashflow and line of sight to future revenues
- As more publishing and design has moved to digital Adobe has been at the forefront of this transition, providing people with the vital tools required for modern designers and marketers – in the digital marketing and design world it's pretty hard to do your job without them these days




Christian Hansen

- A global bioscience company who are one of the leaders in developing natural solutions for the food, nutritional, pharmaceutical and agriculture industries
- The company has a long history of innovation which continues to this day, along with highly scalable production facilities which all provide barriers to entry for competitors wishing to enter the space
- Christian Hansen have been working with microbes for over 145 years so have significant expertise in finding new and useful strains and can then produce them at scale to help their customers
- With health and wellbeing such a significant focus, some of the work Christian Hansen do attempts to effectively help the food and agriculture industry achieve better crop yields and reduce the need for additives, along with providing probiotic supplements for a healthier digestive system
- Finally, there continues to be a significant but vital focus around the world on food waste – Christian Hansen produces solutions to improve freshness, safety, and the life of food products thereby making strides to support the need to reduce food waste



Fund performance



| Discrete annual performance | | | | | |
|-----------------------------|--------------|--------------|--------------|--------------|--------------|
| Year to: | End Sep 2017 | End Sep 2018 | End Sep 2019 | End Sep 2020 | End Sep 2021 |
| Fund | +8.43% | +6.32% | +5.53% | +2.34% | +14.80% |
| UK CPI +3% | +5.96% | +5.68% | +4.83% | +3.20% | +6.32% |

Price performance based upon bid to bid prior to 21 January 2019 and single price (mid) thereafter. Past performance should not be seen as an indication of future performance. The value of investments and the income from them may go down as well as up and you may not get back your original investment.

Our benchmarks are calculated on the rate of change of the CPI index, over different time periods (e.g. if we were calculating year to date figures in January 2020, we would look at the percentage change from December 2019 to the end of January 2020). So we take CPI to the current value, and add on 3%, prorated over a year (roughly 0.25% per month). If the CPI Index benchmark were to fall, more than the amount pro-rata, the benchmark year-to-date will be negative, even though inflation as reported by the media (calculated specifically as a 12M rate of change), remains positive.

| Top performers (%) | | | Bottom performers (%) | | |
|--------------------------|-------------|--------------|----------------------------------|-------------|--------------|
| Holding | Performance | Contribution | Holding | Performance | Contribution |
| Dexcom | +30.90 | +0.27 | Tencent | -19.05 | -0.13 |
| CTS Eventim | +23.51 | +0.09 | Smith & Nephew | -16.24 | -0.15 |
| Rentokil Initial | +18.32 | +0.15 | China AMC China Opportunity Fund | -15.73 | -0.14 |
| Costco | +16.57 | +0.14 | Rio Tinto | -10.49 | -0.10 |
| Thermo Fisher Scientific | +16.09 | +0.13 | Amgen | -9.91 | -0.07 |

Note: Top and bottom performers are taken from the list of all holdings of 0.25% and above of the portfolio. Performance and contribution data shown above is based on unhedged GBP capital returns.

Source: Rathbones

The quarter began on a strong footing for risk assets with markets continuing their ascent and the S&P 500 making new all-time highs again. Bond yields had dipped fairly sharply at the back end of Q2 and that continued in Q3. This was to be short lived though as yields moved significantly higher through September, particularly in the UK with the 10-year now at highs for the year. It would seem those fears around inflation aren't going away as investors and central banks wrestle with the data to figure out whether this inflation is transitory or more likely to hang around. Against that backdrop it was a positive quarter across the portfolio with equities being the main contributor to performance. During the quarter we saw US names like **Dexcom**, **Thermo Fisher Scientific**, and **Edwards Lifesciences** all provide valuable contributions after solid earnings. In Europe we also saw **Eurofins Scientific** report an excellent set of results and rally meaningfully afterwards, along with **ASML** continuing to push higher over the quarter but give back some of that performance at the end of September. We saw meaningful contributions from our **Commodity ETF** exposure as commodity prices moved higher still. Our oil exposure via the oil majors, **Shell**, **BP**, and **Total Energies** were all positive contributors and benefitted as the price of oil pushed on towards, and in the case of Brent crude beyond, \$80 a barrel.

Fund performance (continued)

We saw some pressure on our China exposure in the wake of some of the actions the CCP took against the education sector and some of the technology space in the country. As we have discussed before, we remain comfortable holding the exposure we have at present, but this pressure manifest in negative contributions from **Tencent, AIA**, and the Chinese equity fund we own, **China AMC China Opportunity Fund**. We have also seen continued pressure on **Smith & Nephew** who have been hit by issues around health services getting back on their feet fully in the elective surgeries, which the company is reliant upon within their hip and knee replacement business. The US had shown progress in this area but sadly where a number of states began to see a surge in COVID hospitalisations we saw state governments and hospitals revert back to postponing many non-urgent elective procedures. This is one reason why the fortunes of Smith & Nephew and Edwards Lifesciences has been so different during the year – hip and knee replacements can perhaps be postponed more easily without dire consequences, whereas that is not the case with the heart valve replacement surgeries which Edwards rely upon. Finally, as expected the **put options** were a negative contributor over the quarter as equity markets pushed higher overall.

Asset allocation ranges

| Liquidity | Equity-type risk | Diversifiers |
|-----------|------------------|--------------|
| 5% to 40% | 40% to 80% | 0% to 40% |

Asset allocation change and strategy

We increased our weighting to overseas government bonds, mostly using US inflation-linked bonds, to mitigate the risk of higher inflation. The foreign currency also offers protection against weaker sterling driven by higher local inflation or policy error.

| Asset allocation split | 30.06.21 | 30.09.21 | % Change | | 12 month change | |
|------------------------|----------|----------|----------|---|-----------------|---|
| Liquidity assets | 22.40% | 19.67% | -2.73% | ▼ | -4.32% | ▼ |
| Equity-type risk | 70.04% | 68.77% | -1.27% | ▼ | 1.33% | ▲ |
| Diversifiers | 7.56% | 11.56% | 4.00% | ▲ | 2.99% | ▲ |
| | 100.00% | 100.00% | | | | |

| Asset class split | 30.06.21 | 30.09.21 | % Change | | 12 month change | |
|-----------------------------------|----------|----------|----------|----|-----------------|----|
| Equities | 65.84% | 65.26% | -0.58% | ▼ | 5.49% | ▲ |
| Index-linked bonds | 3.09% | 5.78% | 2.69% | ▲ | 2.10% | ▲ |
| Conventional government bonds | 6.60% | 6.89% | 0.29% | ▲ | -1.53% | ▼ |
| Corporate bonds | 4.94% | 4.68% | -0.26% | ▼ | -0.46% | ▼ |
| Emerging market debt | 3.52% | 3.06% | -0.46% | ▼ | -0.90% | ▼ |
| Private equity | 0.40% | 0.41% | 0.01% | ▲ | -0.03% | ▼ |
| Alternative investment strategies | 3.09% | 5.45% | 2.36% | ▲ | 3.69% | ▲ |
| Property | 0.00% | 0.00% | 0.00% | ◀▶ | 0.00% | ◀▶ |
| Commodities | 1.23% | 2.02% | 0.79% | ▲ | -2.74% | ▼ |
| Cash | 11.29% | 6.45% | -4.84% | ▼ | -5.62% | ▼ |
| | 100.00% | 100.00% | | | | |

For more information on our liquidity, equity-type risk and diversifiers (LED) risk framework, please consult the our investor brochure.

Investment outlook

As 2021 has progressed, risks have risen almost in line with stock markets.

In response to this, we've felt it prudent to take profits from some of our better-performing stocks, particularly those in the technology space that benefited considerably from the shift to remote working and increasingly digital lives. We've been reinvesting that money into two sorts of assets: more cyclical companies that should do well if the economic recovery continues to accelerate, taking inflation with it; and defensive assets that should protect us if inflation gets out of control, interest rates go on a tear or stock markets simply go into reverse.

Don't get the wrong idea – we're not incredibly concerned about the future. On the contrary! We believe the world will mostly likely continue to grow steadily, taking markets with them over the coming years. But asset prices have had a stellar run and people are casting round for worries, so it's no time to be a hero. Best to lock in some profits and make sure we're prepared for the unexpected. That's why we've been piling up the sandbags in our portfolio. We hope we won't have to use them, but it's always best to be prepared.

Rathbone Unit Trust Management Limited
8 Finsbury Circus, London EC2M 7AZ
Tel 020 7399 0000

Information line
020 7399 0399
rutm@rathbones.com
rathbonefunds.com

Authorised and regulated by the
Financial Conduct Authority
A member of the
Investment Association
A member of the Rathbone Group.
Registered No. 02376568

Rathbones
Look forward

Past performance should not be seen as an indication of future performance. The value of investments and the income from them may go down as well as up and you may not get back your original investment.